Effect of Acute Bout of Exercise on Levels of PAHSA
Launched by LENKA ROSSMEISLOVA · Oct 5, 2022
Trial Information
Current as of June 08, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial, called the Effect of Acute Bout of Exercise on Levels of PAHSA (ETAPA), is studying how exercise affects certain substances in the body that may help improve insulin sensitivity. Insulin sensitivity is important for preventing conditions like type 2 diabetes and heart disease, especially in people who are overweight or aging. Researchers want to understand how both short-term and long-term exercise can increase levels of a substance called PAHSA, which has been shown to help reduce inflammation and improve insulin function.
To participate, you need to be a healthy young adult or elderly person, and you should not have certain medical conditions or be taking specific medications that could interfere with the study. Participants will undergo some assessments, which may include blood draws and a small procedure to take a sample of fat from the abdomen. This study is currently looking for volunteers, and it aims to provide important insights that could lead to better treatments for metabolic disorders linked to obesity and aging.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy young lean, young obese and elderly omnivorous men and women as defined by BMI, self-reported activity, self-reported medical history and self-reported diet assessment
- • must be able to withstand repeated blood draws
- • must be able to undergo abdominal fat biopsy
- Exclusion Criteria:
- • use of betablockers
- • use of glucocorticoids
- • use of non-steroidal anti-inflammatory drugs
- • use of metformin in prediabetes
- • use of psychiatric drugs such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, anticonvulsants and others
- • oncologic malignancy
- • chronic inflammatory or autoimmune diseases
- • diabetes mellitus
- • chronic ischemic heart disease
- • cardiovascular and pulmonary disease
- • renal and hepatological disease as assessed per biochemistry
- • musculo-skeletal deviations limiting physical performance
- • substance abuse
- • other than omnivorous diet
About Lenka Rossmeislova
Lenka Rossmeislova is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to ethical standards and rigorous scientific methodologies, the organization collaborates with researchers, healthcare professionals, and regulatory bodies to design and execute clinical trials that address unmet medical needs. By fostering a culture of transparency and collaboration, Lenka Rossmeislova aims to contribute valuable insights to the medical community and facilitate the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Patients applied
Trial Officials
Lenka Rossmeislová, PhD
Principal Investigator
3rd Faculty of Medicine of Charles University in Prague
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials